LONDON—New and comprehensive data showing that millions of cases of breast cancer could be avoided by treating women at high risk of the disease — but who are not yet ill — with the class of drugs known as selective oestrogen receptor modulators (SERMs) have been published in a meta-analysis in The Lancet by researchers from the United Kingdom, Italy and the USA. Jack Cuzick, Professor of Epidemiology at the Wolfson Institute of Preventive Medicine, Queen Mary University of London discussed the latest findings with Peter Goodwin and explained the background and some of the issues which have prevented this effective weapon against breast cancer being widely adopted until now.
You may also like...
Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY 30 Mar, 2018 Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer 12 Feb, 2014 When Good Cells Go Bad: The Stem Cell Origin of Cancers 16 Mar, 2007 Geriatric Assessment Improved Outcomes for Older Patients with Cancer 11 Jul, 2018
- Previous story BRCA-deficient cancers respond to combination of two experimental drugs
- Next story Audio Journal of Oncology with Oncology Times, June 2013
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014